What are the indications for Sutent?

What conditions is Sutent used to treat?

Sutent (sunitinib malate) is a multi-targeted receptor tyrosine kinase (RTK) inhibitor used to treat certain types of cancer [1]. According to the FDA, Sutent is indicated for the treatment of:

* Gastrointestinal stromal tumor (GIST) in patients who cannot take or who have failed other treatments [2].
* Advanced renal cell carcinoma (clear cell) in patients who are not considered candidates for nephrectomy or who have had previous nephrectomy [3].

What happens if a patient has a different type of cancer?

Sutent may also be used to treat other types of cancer, such as pancreatic neuroendocrine tumors (PNET), but these uses are considered "off-label" and not explicitly approved by the FDA [4]. Off-label use means the medication is not approved for that condition but may still be used in clinical practice.

Are there any other approved uses for Sutent?

No, the above-indicated uses are the only approvals granted by the FDA for Sutent. Research and clinical trials are ongoing to explore its potential in other cancer types and conditions.

What should patients know before starting Sutent?

Patients should be aware of the common and serious side effects associated with Sutent, which may include fatigue, diarrhea, hypertension, nausea, anorexia, hand-foot syndrome, and skin rash [5].

References:

[1] National Cancer Institute (May 2020). Sunitinib.

[2] FDA (May 2006). Sutent (sunitinib malate) tablets, for oral use.

[3] FDA (August 2006). Sutent (sunitinib malate) tablets, for oral use.

[4] American Association for Cancer Research (October 2015). Sunitinib.

[5] DrugPatentWatch.com (April 2022). Sutent (sunitinib malate).